KalVista Pharmaceuticals, a Porton Down, UK-based research-led pharmaceutical company, raised $33m in Series B financing.
Backers included Novo A/S, SV Life Sciences, RA Capital Management, Longwood Fund and Venrock. In conjunction with the funding, Rajeev Shah, Managing Director and Portfolio Manager at RA Capital and Rich Aldrich, co-founder and Partner of Longwood Fund, will join KalVista’s Board of Directors. Bong Koh, a Partner at Venrock, and Tomas Kiselak, a Managing Director at RA Capital, will join the Board as observers.
The company, which has raised more than $57m, intends to use the funds to advance its proprietary portfolio of plasma kallikrein inhibitors for treating diabetic macular edema (DME) and hereditary angioedema (HAE).
Led by Andrew Crockett, CEO, KalVista has developed and patented a diverse pipeline of selective and potent plasma kallikrein inhibitors designed for different routes of administration. The most advanced program, an intravitreally administered plasma kallikrein inhibitor, has just completed its first-in-human study and will move into Phase 2 trials in 2016 for the treatment of diabetic macular edema (DME).
The company, which is also advancing orally delivered inhibitors through pre-clinical testing, also has an office in Boston, MA, USA.